Shkreli plots image rehab; Russia approves long-acting Copaxone;

@FiercePharma: Cipla, Serum partner to provide vaccines in S. Africa. More | Follow @FiercePharma

@EricPFierce: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: It's a big day today. Image | Follow @CarlyHFierce

> Martin Shkreli--the CEO of Turing Pharma who faced recent backlash after hiking the price of Daraprim by 5000%--is planning an image rehab, Reuters reports. More

> The Russian ministry of health has approved the 40mg version of Teva's ($TEVA) Copaxone. Report

> AstraZeneca ($AZN) has launched its Moventig in England and Wales. Report

> Impax Labs ($IPXL) has appointed Janet Vergis to its board of directors. Release

> Shanghai Pharmaceuticals has teamed up with DXY, one of China's largest online pharmaceutical platforms, to create better e-clinics. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: GE Ventures reaffirms commitment to VC with med tech startup program. Article | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2

@EmilyWFierce: OKs expanded label for InSightec's noninvasive ultrasound fibroid device. News | Follow @EmilyWFierce

> Harvard's Wyss launches Opsonix, backed by Baxter in $8M to get sepsis device into clinic. More

> Study shows UV light-emitting robot reduces hospital-associated infections by 30%. Article

Biotech News

@FierceBiotech: Wyss spins out pathogen-capturing tech into upstart biotech. Story | Follow @FierceBiotech

@JohnCFierce: CDK 4/6 inhibition (no. 2) With FDA 'breakthrough' in hand, Eli Lilly shoots for accelerated abemaciclib OK. Report | Follow @JohnCFierce

> With FDA 'breakthrough' in hand, Eli Lilly shoots for accelerated abemaciclib OK. Story

> The most hated man in biotech is still confident of a comeback. Editor's corner

> Octapharma buys into Glycotope with an €80M cash deal. News

> Feeling the biotech chill, CytomX stumbles onto Nasdaq with an $80M IPO. Article

Vaccines News

> FDA puts clinical hold on Advaxis' cervical cancer vaccine. More

> Allegheny General Hospital joins Sanofi's Cdiffense PhIII trial. Report

> Cipla, Serum partner to provide vaccines in S. Africa. Story

> Pfizer completes acquisition of two GSK meningitis vaccines. Item

> With PhII data, Genocea's herpes jab continues on blockbuster path, CEO says. Article

CRO News

> WuXi takes its genomics biz to Qatar with new hospital partnership. Report

> Evotec inks a $4.9M deal for oncology R&D. More

> PPD signs a pair of federal deals for battlefield health, flu readiness. Story

> INC bolsters its Phase I platform with new cardiac tech. Item

> Charles River signs a trio of deals in drug discovery. Article

Pharma Manufacturing News

> Cipla moves forward with deal for plant in Algeria. Item

> Investor buys Italian CDMO with plans to roll up others. Report

> Hospira manufacturing mess-up leads to PharMEDium recalls. Story

> Sanofi puts Allegra plant in U.S. back up for sale. Article

Pharma Asia News

> Japan's SymBio partners with Medicines Co. on pain reliever Ionsys. Item

> China gets its due with Nobel, but research problems still remain. Report

> China Biologic subsidiary inks deal to source raw plasma. More

> Singapore's TauRx completes $135M fundraising for PhIII Alzheimer's work. Article

> China's BeiGene snaps up Pfizer executive to run manufacturing ops. Story

And Finally... Elephants hardly ever get cancer, and now researchers think they know why. Story

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.